ACS APPLIED MATERIALS & INTERFACES

www.acsami.org

Research Article

¹ Ultrasmall AgNP-Impregnated Biocompatible Hydrogel with Highly ² Effective Biofilm Elimination Properties

3 Hanif Haidari, Zlatko Kopecki, Richard Bright, Allison J. Cowin, Sanjay Garg, Nirmal Goswami,* 4 and Krasimir Vasilev*

Cite This: http:	s://dx.doi.org/10.1021/acsami.0c	09414	Read Online	
ACCESS	III Metrics & More		E Article Recommendations	s Supporting Information

5 ABSTRACT: Ultrasmall silver nanoparticles (AgNPs; size < 3 nm) have 6 attracted a great deal of interest as an alternative to commercially available 7 antibiotics due to their ability to eliminate a wide range of microbial pathogens. 8 However, most of these ultrasmall AgNPs are highly reactive and unstable, as 9 well as susceptible to fast oxidation. Therefore, both the stability and toxicity 10 remain major shortcomings for their clinical application and uptake. To 11 circumvent these problems, we present a novel strategy to impregnate ultrasmall 12 AgNPs into a biocompatible thermosensitive hydrogel that enables controlled 13 release of silver alongside long-term storage stability and highly potent 14 antibacterial activity. The advantage of this strategy lies in the combination of 15 a homogenous dispersion of AgNPs in a hydrogel network, which serves as a 16 sustained-release reservoir, and the unique feature of ultrasmall AgNP size, which 17 provides an improved biofilm eradication capacity. The superior biofilm



18 dispersion properties of the AgNP hydrogel is demonstrated in both single-species and multispecies biofilms, eradicating ~80% 19 of established biofilms compared to untreated controls. Notably, the effective antibacterial concentration of the formulation shows 20 minimal toxicity to human fibroblasts and keratinocytes. These findings present a promising novel strategy for the development of 21 AgNP hydrogels as an efficient antibacterial platform to combat resistant bacterial biofilms associated with wound infections.

22 **KEYWORDS:** ultrasmall silver nanoparticles, hydrogel, antibacterial nanoparticles, topical delivery of silver nanoparticles, 23 multispecies biofilm disruption

24 INTRODUCTION

25 The rise in antibiotic resistance is becoming a major health 26 threat globally, which accounts for the deaths of 23 000 people 27 annually in the United States alone. The estimated global 28 human death toll is expected to be 10 million by 2050 as a 29 direct result of antibiotic-resistant infection. $^{1-3}$ Persistent 30 bacterial wound infections are mediated by highly organized 31 structures known as biofilms, which are communities of 32 bacteria and extracellular matrix where individual cells have 33 close interactions and produce a protective substrate to which 34 they adhere.⁴ Unlike bacteria in a planktonic state, biofilms 35 present many challenges, predominately due to their inherent 36 resistance to both antimicrobials and natural host defenses.^{5,6} 37 The rapid emergence of drug-resistant bacterial infections and 38 the challenges associated with the treatment of biofilms 39 highlight the demand for alternative antimicrobial agents that 40 provide effective solutions against this clinical problem.

⁴¹ Current antimicrobial strategies include the use of ⁴² antibiofilm coatings, which are effective in eliminating both ⁴³ single- and multispecies bacterial cultures.^{7–9} However, a ⁴⁴ substantial challenge is presented when bacteria become ⁴⁵ encased in protective polymeric substances and form biofilms. ⁴⁶ These biofilms tend to become resistant to many of the traditionally used antibiotics due to alterations in phenotype, 47 their acquisition of a physical barrier, and extended bacterial 48 life cycles.^{10,11} 49

Local wound infections that resist treatment by traditional 50 antibiotic strategies are susceptible to transform into severe 51 chronic infections and systemic sepsis resulting in serious 52 health consequences. In most cases, chronic wound biofilms 53 are very complex and consist of multispecies pathogens.¹² This 54 leads to challenging consequences including increased biofilm 55 biomass and elevated resistance to antimicrobial agents as well 56 as greater bacterial pathogenicity.^{13,14} For example, a 57 significant increase in antibiotic tolerance in multispecies 58 biofilms was observed *in vitro*, which leads to longer treatments 59 with higher drug concentrations, which in turn further 60 contributed to the development of antibiotic resistance.¹⁵ 61

 Received:
 May 23, 2020

 Accepted:
 August 25, 2020

 Published:
 August 25, 2020



111





As traditional commercial antimicrobials have failed to 62 63 mitigate the threat of antibiotic resistance, other materials, 64 including silver nanoparticles (AgNPs), have emerged as 65 potential alternatives due to their broad-spectrum antimicro-66 bial actions.^{16–19} We have recently reported that mercapto-67 succinic acid (MSA)-coated AgNPs (AgNPs@MSA) with size \sim 3 nm show excellent antibacterial activity against bacteria in 68 69 their planktonic state.²⁰ However, these ultrasmall AgNPs are 70 highly susceptible to fast oxidation that leads to rapid silver ion 71 release, resulting in an only short-term activity that limits their 72 tractability in antimicrobial applications.²¹ Additionally, when 73 the local concentration of silver ions is high, healthy cells are 74 also susceptible to the toxic effects of silver. Thus, the use of 75 lower concentrations of AgNPs alongside slower release while 76 still showing strong bactericidal activity is a desirable way to 77 reduce unwanted cellular toxicity.

The goal of this study was to overcome the current shortfalls 78 79 of silver as an antimicrobial agent by incorporating AgNPs in a 80 hydrogel to provide a controlled and localized delivery 81 platform (Scheme 1). This strategy would enable the delivery 82 of AgNPs at the target site (e.g., an infected wound) and in an 83 adequate concentration to eliminate bacterial pathogen colonization without toxic side effects to mammalian cells. 84 85 Another, even more ambitious goal was to eliminate 86 established biofilms. We hypothesized that the ultrasmall size 87 of the AgNPs would penetrate the dense extracellular matrix of 88 bacterial biofilms, hence facilitating enhanced killing and 89 elimination of the pathogens. Lastly, the hydrogel formulation 90 would be safe and nontoxic to mammalian cells in a wound 91 environment, which is a critical requirement for biomedical devices in these clinical settings. 92

s1

⁹³ Pluronic F-127 polymer was utilized as a carrier for the ⁹⁴ AgNPs as this triblock copolymer possesses excellent ⁹⁵ thermoreversible properties in aqueous solution. Also, it is ⁹⁶ generating growing interest as a carrier for nanomaterials due ⁹⁷ to its excellent solubility and stability.²² Furthermore, Pluronic ⁹⁸ F-127 is both biocompatible and Food and Drug Admin-⁹⁹ istration (FDA)-approved, which is important for the develop-¹⁰⁰ ment of antibacterial platforms for the treatment of infected ¹⁰¹ wounds.²³⁻²⁶

The antibacterial performance of the delivery system was investigated against both Gram-negative and Gram-positive bacteria in both planktonic and biofilm states, including multispecies biofilms. The safety of the AgNP formulation was evaluated against human keratinocytes and fibroblasts to row ensure a lack of toxicity and a high degree of biocompatibility. The development of this nanocomposite offers new hope to 108 elucidate drug resistance and improve wound-infection-related 109 treatment outcomes in clinical settings.

EXPERIMENTAL SECTION

Materials. AgNO₃ (99.99%), mercaptosuccinic acid (MSA), 112 sodium borohydride (NaBH₄), Pluronic F-127, propylene glycol 113 (PG), resazurin sodium salt, 2',7'-dichlorofluorescin diacetate 114 (DCFH-DA), nitric acid (HNO₃), sodium hydroxide (NaOH), and 115 hexamethyldisilazane (HMDS) were purchased from Sigma-Aldrich 116 (Sydney, Australia). All other reagents used throughout the study 117 were of analytical grade, commercially available, and used without 118 further purifications. Ultrapure water with 18.2 M Ω (Millipore) was 119 used in all syntheses and preparations. 120

Synthesis of MSA-Coated AgNPs. For the preparation of the 121 MSA-coated AgNPs, 1 mL of 20 mM AgNO₃ and 1 mL of 20 mM 122 MSA were first mixed in 7.7 mL of MilliQ water under vigorous 123 stirring (ice-cold condition) to form Ag(I)–thiolate complexes. After 124 a 5 min stirring, 0.3 mL of 0.05 M NaBH₄ (prepared in 20% 1 M 125 NaOH) was introduced to the reaction mixture. Subsequently, the 126 reaction was stirred at 500 rpm for 24 h. The slow progress of color 127 change from pale to bright yellow confirmed the formation of 128 AgNPs@MSA. After the synthesis, the NP solution was purified 129 through dialysis (Pur-A-Lyzer Maxi Dialysis Kit; MWCO 3.5 kDa) 130 against ultrapure water, lyophilized using Modulyo freeze, and stored 131 for further use. Under the same synthesis conditions, the scalability of 132 AgNPs@MSA was verified for up to 250 mL of total solution.

Preparation of Pluronic Hydrogel. The Pluronic F-127 134 hydrogel base was prepared based on the cold method described 135 previously.²⁷ The hydrogel was prepared by adding the preweighed 136 quantity of Pluronic F-127 and Propylene glycol slowly to MilliQ 137 water with or without AgNPs, keeping the system in a cold bath. The 138 resulting formulation was transferred to the refrigerator at 4 °C 139 overnight to ensure the complete dissolution of PF-127. 140

Characterization of AgNPs. The optical properties of the 141 purified AgNP solution were characterized using UV–vis spectroscopy (Shimadzu 2600, Japan). The optical properties of AgNPs in the 143 formulation were determined by diluting the hydrogel in 1:3 with 144 MilliQ water. Dynamic light scattering (DLS) (Malvern Zetasizer 145 Nano) was used to measure the hydrodynamic diameter and ζ - 146 potential of the samples. The primary size and morphology of AgNPs 147 were determined by transmission electron microscopy (TEM) (JEOL 148 3010) operating at 200 kV. The AgNP size distribution was 149 determined by counting over 250 nanoparticles using ImageJ software 150 (Fiji).

Characterization and Evaluation of Thermosensitive Hydro- $_{152}$ gel. The silver concentration in the hydrogel was verified using $_{153}$ inductively coupled optical emission spectroscopy (ICP-OES). For $_{154}$ this, 1 mL of the gel formulation was dissolved in 4 mL of HNO₃ $_{155}$ (70% v/v) and it was brought to a volume of 10 mL with MilliQ $_{156}$

157 water. The resulting solution was filtered (0.25 μ m), and the silver 158 concentration (atomic) was analyzed using ICP-OES.

AgNP Formulation Stability. The effect of short-term storage 1.59 160 condition on AgNP formulation and AgNP solution was studied at 161 three different storage temperatures (fridge 4 °C, room temperature 162 25 °C, and incubator 37 °C) covered with an aluminum foil. At 163 different time intervals of 0, 7, 30, and 60 days, a representative batch 164 was withdrawn and subjected to UV-vis, DLS, and ζ -potential 165 measurements. AgNPs were monitored over time based on their 166 chemical and physical properties at different temperature conditions. Rheological Properties. The rheological experiments were 167 168 carried out on a rheometer (TA instrument) using a parallel plate 169 with a diameter of 25 mm. The oscillatory shear rate sweep was 170 carried out at a constant temperature of 25 °C and a shear rate of 1-171 200 s⁻¹. Additionally, rate sweep measurements were also conducted 172 to determine the hydrogel viscosity. The temperature analysis of the 173 hydrogel was measured using a single frequency strain-controlled 174 temperature ramp from 20 to 40 °C at constant shear stress (0) and 175 strain of 1% to acquire the storage modulus (G') and loss modulus 176 (G'') with respect to temperature.

177 **Thermogravimetric Analysis (TGA).** Thermal analysis of the 178 blank hydrogel and the silver hydrogel was measured using TGA (TA 179 instruments Discovery). Approximately 5 mg of sample was placed in 180 an open pan (platinum) attached to a microbalance. The samples 181 were heated at 20 $^{\circ}$ C/min from 25 to 700 $^{\circ}$ C under dry nitrogen with 182 a flow rate of 10 mL/min in the standard mode with a ramp test type. 183 All of the measurements were performed in duplicate.

Scanning Electron Microscopy (SEM). The microstructure of 185 the hydrogel was examined using scanning electron microscopy 186 (SEM) (Zeiss Merlin FEG). The swollen hydrogel samples were 187 transferred to liquid nitrogen and then freeze-dried under vacuum for 188 24 h or until completely dry. The dried hydrogels were mounted on 189 SEM stubs and sputter-coated with platinum and then imaged using a 190 scanning electron microscope at 2 kV at different magnifications ($10\times$ 191 and $30\times$). The composition of major elements present on the surface 192 of the AgNP hydrogel was analyzed using energy-dispersive X-ray 193 spectrometer (EDS) mapping at an acceleration voltage of 15 kV 194 (SEM Zeiss Merlin FEG with SDD EDS).

In Vitro Release Study. The in vitro release of AgNPs from the 195 196 prepared hydrogel formulations was studied using a dialysis 197 membrane approach. Dialysis (12 kDa CelluSep Western Australia) 198 was presoaked in MilliQ water for 1 h prior to the experiment and 199 then rinsed with water to remove preservatives. Two milliliter samples 200 of the formulation were dispensed into the dialysis membrane as a 201 donor compartment. The bag was firmly tied and immersed into a 50 202 mL falcon tube (receptor compartment) containing 10 mL of 203 phosphate-buffered saline (PBS) pH 7.4 as the release medium. The 204 system was maintained at 37 \pm 0.5 °C in a thermostatically controlled 205 shaking incubator at ~85 rpm. Aliquots of 2 mL were withdrawn at 206 intervals of 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 h, which were replaced by 207 the same volume of fresh solution (kept at the same temperature) to maintain a constant volume. The collected solution was diluted 208 209 accordingly to be analyzed by ICP-OES. The experiment was 210 conducted using two replicates on three different occasions.

²¹¹ In Vitro Antibacterial Evaluation of AgNPs. Bacterial Strains ²¹² and Culture. Staphylococcus epidermidis ATCC 35984, Staphylococcus ²¹³ aureus ATCC 25923, Escherichia coli 10P50, and Pseudomonas ²¹⁴ aeruginosa PAO1 were streaked on Mueller Hinton Agar (MHA) ²¹⁵ plates. Bacterial cultures were prepared by isolating a single colony ²¹⁶ and suspending it in 10 mL of sterile tryptic soy broth (TSB) medium ²¹⁷ incubated overnight (16–18 h) at 37 °C in a shaking incubator. The ²¹⁸ optical density was measured at 660_{nm} (OD 660) and standardized by ²¹⁹ diluting the overnight culture to 0.25, which equates to approximately ²²⁰ 2.5 × 10⁸ colony-forming units (CFU)/mL. The resulting stand-²²¹ ardized inoculum was further diluted as required.

222 Well Diffusion Assay. Overnight culture of bacterial strains was 223 adjusted to OD 660_{nm} 0.25 and diluted further to obtain 1×10^{6} 224 CFU/mL. The bacterial lawn was prepared by adding 100 μ L of 225 diluted inoculum onto the diagnostic sensitivity test agar surface 226 (Oxoid) and spread uniformly. A well with a diameter of 6 mm was punched aseptically with a sterile cork borer, and a volume of 100 μ L 227 of the formulation and positive control (ciprofloxacin) and negative 228 controls (TSB) were introduced into the well. The agar plates were 229 incubated at 37 °C overnight (16–18 h), and the zone of inhibition 230 (mm) was measured the following day. 231

Live/Dead Viability Assay. The bacterial viability was quantita- 232 tively evaluated using the Live/Dead Baclight viability kit as per the 233 manufacturer's manual (Invitrogen, Thermo Fisher Scientific). An 234 overnight culture of bacteria was cultured in TSB at 37 $^\circ C$ and then $_{235}$ diluted to 1×10^6 CFU/mL in fresh TSB. Aliquots of the bacterial 236 suspension were grown on a sterile glass coverslip and treated with 237 extracts of the test formulation hydrogel (25 μ g/g, 50 μ g/g, and blank 238 at final concentrations) and 50 μ g/mL ciprofloxacin as the positive 239 control and the negative control. The extracts of the silver hydrogel 240 were prepared by incubating the pure silver formulation (100 μ g/g, 50 241 μ g/g, and blank gel) in TSB (1:1) for 24 h at a 37 °C incubator. After 242 overnight incubation at 37 °C, the wells were gently washed with PBS 243 to remove unadhered bacteria. Then, the bacterial cells were stained 244 with a working concentration (1:1) of 3 μ L/mL PBS of SYTO9 and 245 propidium iodide. The samples were incubated in the dark for 15 min 246 at 25 °C, followed by a PBS wash. The glass coverslips were mounted 247 on a microscope slide to be imaged via an Olympus FV3000 confocal 248 laser scanning microscope (CLSM). The number of live and dead 249 cells was quantified using ImageJ software (Fiji)1.52a. 250

In Vitro Biofilm Formation Assay (Crystal Violet). Sterile 251 polystyrene flat-bottom 96-well plates were inoculated individually 252 with standardized S. epidermidis, P. aeruginosa, and S. aureus 253 suspensions at 10⁶ CFU/mL. For multispecies biofilms, the individual 254 bacteria were standardized to 10⁶ CFU/mL and then combined at 255 equal volumes (60 μ L) with other bacteria to acquire a total of 180 μ L 256 of mixed bacterial population. The plates were incubated in a humid 257 chamber for 24 h at 37 °C. After the incubation period, the planktonic 258 bacteria were removed from each well and the wells were washed with 259 PBS to remove any loosely attached cells. Then, 150 µL of TSB 260 containing different concentrations of the test formulations and 261 antibiotic control (50 μ g/mL ciprofloxacin) was added to the wells 262 and incubated for 24 h at 37 °C. The wells were washed with PBS and 263 fixed with 10% formaldehyde for 15 min, followed by a further PBS 264 wash. The biofilms were stained with 0.1% crystal violet (CV) for 15 265 min at room temperature, and the plate was washed with PBS and air- 266 dried. The crystal violet-bound cells were solubilized with 33% acetic 267 acid, and the released stain was measured at 550 nm using a 268 microplate reader (ELx800 Microplate Reader, BioTek). The biofilm 269 analysis was performed on three independent occasions. 270

In Vitro Wound Biofilm Model. The wound biofilm model was 271 conducted on a permeable membrane over a semisolid agar surface 272 that facilitates the model to resemble wound biofilms, according to 273 Thet et al., with slight modification.²⁸ In brief, a polycarbonate 274 membrane with an average pore diameter of 200 nm (Whatman) was 275 UV-sterilized (15 min) and placed on brain heart infusion (BHI) agar. 276 Then, the surface of the membrane was preconditioned with artificial 277 acute wound fluid (30 μ L of human serum containing 5% blood and 278 1% peptone) and allowed to dry. Bacterial overnight cultures of P. 279 aeruginosa, S. epidermidis, and S. aureus were adjusted to OD 660_{nm} 280 0.25 and further diluted in 1/100 before being spotted in the center of 281 each membrane (50 μ L). After 24 h of biofilm growth at 37 °C, the 282 membranes were aseptically transferred to new BHI agar, and biofilms 283 were treated with 100 μ L of different doses of AgNP gel (25 and 50 284 μ g/g) and ciprofloxacin (50 μ g/mL). After further 24 h of incubation, 285 the membrane was removed, and the biofilm was stripped off from the 286 membrane in 5 mL of PBS by a series of vigorous 2X vortexing (1 287 min) and 2X sonication (15 min) before being serially diluted in PBS 288 and subjected to standard CFU counts per membrane.

Confocal Laser Scanning Microscopy (CLSM) Assessment of 290 Biofilm Disruption. A sterile glass coverslip was placed at the bottom 291 of 24-well plates and inoculated with 1×10^6 CFU/mL of *P*. 292 *aeruginosa*. For multispecies biofilms, the individual bacteria were 293 standardized to 10^6 CFU/mL and then combined at an equal volume 294 of 60 μ L with other bacteria to acquire a total of 180 μ L of a mixed 295 bacterial population. The plates were statically incubated for 24 h at 296 297 37 °C in a humid chamber as described above. The planktonic cells 298 were gently washed, and the biofilms were treated with 500 μ L of test 299 formulation extracts (final concentrations 25 and 50 μ g/g) together 300 with 50 μ g/mL ciprofloxacin and the negative control. After a further 301 24 h of incubation at 37 °C, the coverslips were washed and then 302 stained with 3 μ m of SYTO9 and propidium iodide followed by 15 303 min in the dark at 25 °C. The excess stain was washed and mounted 304 on a glass slide for confocal imaging. Images were visualized under 305 CLSM and processed with Bitplane Imaris v9.0 3D/4D image analysis 306 software.

Scanning Electron Microscopy (SEM) Analysis of Biofilm 307 308 Structure. The morphology of the biofilm architecture was analyzed 309 using SEM following established protocols.²⁹ The bacteria were 310 cultured on a sterile glass coverslip for 24 h. The biofilms grown on 311 the surface were gently washed with PBS and treated with extracts of 312 test formulation (25 and 50 μ g/g) alongside the relevant controls. 313 Biofilms were fixed overnight with 1.25% glutaraldehyde and 4% 314 paraformaldehyde in PBS containing 4% sucrose pH 7.4. Samples 315 were then washed in PBS, followed by dehydration in an ascending 316 ethanol series from 50% (v/v) to absolute ethanol. Samples were then 317 chemically dried using hexamethyldisilazane (HMDS) and mounted 318 on aluminum stubs, sputter-coated with 1 nm platinum, and examined 319 in a Zeiss Merlin FEG SEM scanning electron microscope. Images 320 were acquired using 2 kV at a working distance of ~4 mm. Each 321 sample was analyzed for four images at different locations and 322 magnifications.

Measurement of Reactive Oxygen Species (ROS). To determine 323 324 the generation of intracellular reactive oxygen species (ROS) as a potential cellular response to AgNPs, an ROS indicator 2,7-325 326 dichlorofluorescin-diacetate (DCFH-DA) (Sigma-Aldrich, Australia) 327 was used. This dye is a cell-permeant, which becomes fluorescent 328 when cleaved by intracellular esterase and oxidized by intracellular 329 reactive species.³⁰ An overnight P. aeruginosa suspension was 330 standardized to 10⁶ CFU/mL, and 100 μ L was transferred to each well of a 96-well plate for overnight growth. The cells were collected 331 332 by centrifugation and washed with PBS and then incubated with 20 333 μ m of DCFH-DA at 37 °C for 30 min in the dark. Following staining, 334 the cells were washed and subjected to treatment of AgNP 335 formulation extracts (25 and 50 μ g/g) including positive control of 336 1 mM hydrogen peroxide (H_2O_2) . The samples were incubated for 3 337 h at 37 °C in the dark, reading the fluorescence intensity every 30 min 338 using a plate reader (Enspire PerkinElmer Multimode plate reader) with excitation at 485 nm and emission at 530 nm. 339

Cytotoxicity Studies. The resazurin assay was performed to 340 341 determine the cell viability based on metabolically active cells as per 342 the method described previously.⁹ Briefly, human foreskin fibroblasts 343 (HFFs) and human keratinocytes (HaCaTs) were seeded in 96-well 344 tissue culture plates at a density of 4×10^4 cells/well in Dulbecco's 345 modified Eagle's medium (DMEM), supplemented with 10% fetal 346 bovine serum (FBS) and 5% penicillin and streptomycin and 347 incubated at 37 °C in 5% CO2 for 24 h. The cytotoxic effect of the 348 silver formulation gel was assessed according to the previously 349 described method using material extracts.³¹ Extracts of the silver 350 hydrogel were prepared by incubating the pure silver formulation 351 (blank gel, 50 μ g/g, and 100 μ g/g) in DMEM (1:1) without FBS for 352 24 h at 37 °C in an incubator. After attaining approximately 90% 353 confluency, the wells were washed with PBS and subsequently cells were treated with formulation extracts 100 μ L supplemented with 354 355 10% FBS. Cells treated with fresh DMEM were used as controls. After 356 further incubation for 24 h, the cells were washed and resazurin dye 357 was added. The stock concentration of resazurin (110 μ g/mL) was 358 diluted 1:10 in DMEM, and the working solution was added to the 359 wells. The cells were incubated for 2 h at 37 °C in an incubator and 360 then the fluorescence intensity of the dye was measured using a plate 361 reader (BMG LabTech, Australia).

Fluorescence Staining of Cell Morphology. The effect of gel scalar extracts on HFFs and HaCaT cell morphology was determined using fluorescence staining. The existing cultured cells in 96-well plates were set treated similarly as described above. The adherent cells were fixed side with 3.7% formaldehyde for 10 min at room temperature, washed, and

377

membrane-permeabilized with 0.1% Triton X-100 for 5 min before 367 staining. The cells were stained with Phalloidin Oregano green 488 368 (Invitrogen, Thermo Fisher Scientific) for 20 min in the dark at a 369 working concentration of 1:40 in PBS. The cellular nuclei were 370 stained with diamido-2 phenyllindole dihydrochloride (DAPI) in 371 (1:1000) PBS for 10 min. After staining, the cells were briefly washed 372 and were imaged using an Olympus fluorescence microscope at 373 different magnification. The images were analyzed and processed 374 using CellSens software (Olympus Life Science, Australia) following 375 established protocols.³²

RESULTS AND DISCUSSION

Synthesis and Characterizations of AgNPs@MSA. The 378 MSA-capped AgNPs were synthesized in a process similar to 379 our previously published protocol, through a reduction 380 decomposition reaction with slight modifications to improve 381 size distribution and scalability.²⁰ Briefly, the calculated 382 amounts of AgNO₃ and MSA were mixed under ice-cold 383 conditions to form the Ag–thiol complex, followed by the 384 addition of NaBH₄ to initiate reduction decomposition as 385 depicted in the scheme in Figure 1A. The formation of 386 fil



Figure 1. (A) Formation of MSA-protected AgNPs by cyclic reduction decomposition. (B) UV-vis absorption spectra of AgNPs and the controls; the inset is a representative photo of the AgNPs@MSA solution. (C) TEM micrographs of AgNPs; the inset shows the nanoparticle size distribution.

AgNPs@MSA (yellow peak) was confirmed using UV–vis $_{387}$ spectroscopy, which shows distinct differences in the MSA $_{388}$ (green) and Ag⁺ (blue) spectra. The resultant solution was $_{389}$ bright yellow, as shown in the inset in Figure 1B. The UV–vis $_{390}$ spectra showed the absence of plasmon resonance absorption, $_{391}$ which is a characteristic of ultrasmall AgNPs, consistent with $_{392}$ previous reports. $_{33}^{33}$ The ultrasmall size of the nanoparticles was $_{393}$ further confirmed by TEM analysis, revealing a core diameter $_{394}$ of 2.98 \pm 0.85 nm (Figure 1C). Additionally, the TEM analysis $_{395}$ correlated well with DLS measurements (Figure S1).

Hydrogel Preparation and Characterizations. The 397 Pluronic F-127 thermosensitive hydrogel was prepared by 398 controlled loading of ultrasmall silver nanoparticles (AgNPs@ 399 MSA) at various concentrations (25, 50, 100, 150, and 200 μ g/ 400 g). Pluronic F-127 is a well-accepted biocompatible drug 401 carrier commonly used in topical applications. This hydrogel 402 has known wound-healing properties that include improved 403 cell proliferation.^{34,35} Additionally, the Pluronic F-127 hydro- 404 gel also possesses thermoresponsive properties and undergoes 405 reversible phase transitions at a lower critical solution 406



Figure 2. (A) Shear stress in response to the shear rate of the blank and the AgNP hydrogel. (B) Viscosity of the hydrogel as a function of time. (C, D) Temperature dependence of storage modulus (G') and loss modulus (G'') of the blank and the AgNP gel.

407 temperature (LCST).³⁶ Utilizing the Pluronic F-127 hydrogel 408 has advantages including simplicity of preparation and absence 409 of extreme conditions including heating and organic solvents, 410 which could lead to AgNP aggregation. Changes in the AgNP surface charge and chemistry may cause the particles to 411 412 become unstable and aggregate, hence resulting in changes to 413 the intended biological activity. Following a well-rationalized 414 preparation approach, Pluronic F-127 in combination with 415 propylene glycol presented optimal thermoresponsive behavior 416 (components of the hydrogel are listed in Table S1). The 417 addition of propylene glycol was important to improve the 418 consistency of the hydrogel as well as the development of a gel 419 network while serving as a stabilizing emulsion. Propylene 420 glycol modulates self-assembly of the triblock polymer due to 421 its relative polarity to the domain structure of the gel.³⁷ It 422 enhances the hydrogen bonding between water and gelling 423 agents, thereby affecting the swelling and viscoelastic behavior 424 of the polymeric network.³⁸

Rheological Properties. The mechanical properties and 426 solution to gel transition of the hydrogel were studied by 427 dynamic rheology. The results of the rheological measurements 428 are presented in Figure 2A–D. Figure 2A shows oscillatory 429 shear rate sweeps of the Pluronic F-127 hydrogel in the 430 presence of AgNPs, consistent with non-Newtonian fluids 431 exhibiting shear-thinning behavior.³⁹ This suggests that the 432 viscosity of the hydrogel decreases upon application of stress

f2

and there is rapid retention of its mechanical properties when 433 the stress is reduced. Furthermore, as the shear rate increased, 434 the viscosity reduced with no major changes observed among 435 the blank or the AgNP hydrogel (Figure 2B). Next, the 436 dependence of the storage modulus (G') and loss modulus $_{437}$ (G'') was studied to determine the thermoresponsive behavior 438 of the hydrogel. In this context, G' reflected the solidlike 439 component dominant at a lower temperature but increased at 440 the gelation point.⁴⁰ As shown in Figure 2C,D, the solution/gel 441 transition temperature of the storage modulus (G') and the 442 loss modulus (G'') of the blank gel was equal at the 443 temperature of ~28 °C compared to ~34 °C for the AgNP 444 gel. The temperature sweep measurements show that the 445 presence of AgNPs elevated the gelation temperature. This 446 indicates that the AgNPs may contribute to hydrogen-bonding 447 interactions and greater cross-linking density of the hydrogel. 448 Additionally, the transition temperature of this hydrogel is 449 physiologically relevant to topical application in clinical use. 450

Hydrogel Formulation Stability. The prepared AgNP 451 formulation was evaluated by UV–vis spectroscopy and 452 dynamic light scattering (DLS) to monitor and determine 453 the optimal storage condition. Given the complex nature of the 454 hydrogel being composed of many ligands, molecules, and 455 ions, it was critical to assess the stability of AgNPs in this 456 environment. The results of UV–vis spectroscopy show that 457 AgNPs loaded in the hydrogel have similar absorption spectra 458 f3



Figure 3. (A) UV-vis spectra of gels with and without AgNPs. (B) Thermogravimetric analysis of AgNP-loaded hydrogel and controls. (C) AgNP release profile from the hydrogel over a 24 h period.

459 compared to AgNPs in solution (Figure 3A). The observed 460 peak remained unchanged after 2 months of aging time at the 461 storage temperatures of 4 and 25 °C, indicating the highly 462 stable nature of the nanoparticles (Figures S1-S4). Similarly, 463 the size of the nanoparticles remained unchanged over time as 464 reflected by the DLS analysis at 4 and 25 °C storage on day 0 465 (Figure S1) and day 60 (Figure S4). The slight increase in size 466 observed at higher temperatures (37 °C) after 2 months is 467 expected as this condition favors the NP collision rate and 468 subsequently induces faster agglomeration compared to the 469 lower temperature. This was reflected in both UV-vis spectra 470 and DLS measurements showing a slight shift in the absorption spectra and overall size distribution to the right. In contrast, at 471 472 4 and 25 °C storage, the gel displays a state of well-dispersed 473 particles, as expected from an ideal stabilized system. The 474 analysis of the physical state of the nanoparticles suggests that 475 the AgNPs have maintained their native optical and physical 476 properties after incorporation into the hydrogel network 477 without any major alteration. More importantly, this data 478 indicates that AgNPs@MSA are stable in the hydrogel, and 479 Pluronic hydrogel presents a compatible carrier for silver delivery in vivo. 480

481 **Thermogravimetric Analysis of the Hydrogel (TGA).** 482 Thermogravimetric analysis (TGA) was used to study the 483 decomposition pattern and thermal stability of the native 484 Pluronic hydrogel and the corresponding AgNP-loaded 485 counterpart. The TGA spectra (Figure 3B) show the weight-486 loss pattern of the hydrogels and their components between 20

and 700 °C. Both hydrogels exhibited two weight-loss stages. 487 The initial weight loss in the blank hydrogel appeared in the 488 range of 50-130 °C, which is due to the evaporation of the 489 adsorbed water. The major weight loss appeared in the range 490 of 250-350 °C, which is attributed to the degradation of 491 molecular chains.⁴¹ However, the incorporation of AgNPs in 492 the hydrogel improved the thermal stability, leading to a higher 493 decomposition temperature (430 °C) and a slower thermal 494 decomposition rate. The increased stability could be attributed 495 to the formation of a stable hydrogen bond between the 496 nanoparticles and the polymer and an increase in the molecular 497 mass.⁴² Additionally, the presence of AgNPs@MSA may 498 contribute to a greater cross-linking density and subsequently 499 a more compact structure, which may result in enhanced 500 mechanical properties of the hydrogel. The AgNPs@MSA 501 alone and its respective ligand shell (MSA) showed 502 significantly different properties. The significant thermal 503 stability of AgNPs@MSA could also be attributed to the 504 strong thiol interaction (MSA) with the metal atoms, which 505 results in the formation of a thermodynamically stable system. 506 The TGA profiles for functionalized AgNPs are consistent with 507 published studies reporting a three-stage weight loss and a 508 significantly slower decomposition rate as previously re- 509 ported.43 510

In Vitro Release from Pluronic Hydrogel. The release 511 behavior of silver from the Pluronic thermosensitive hydrogel 512 was studied in PBS (pH 7.4) at 37 °C, which closely resembles 513 the physiological conditions. The percentage of silver released 514



Figure 4. SEM micrograph of the blank hydrogel (A, B) and the hydrogel loaded with AgNPs (C, D) at two different magnifications. (E-H) EDS mapping of major elements present on the surface of the AgNP-loaded hydrogel.



Figure 5. Antibacterial properties assessed via the disk diffusion assay. (A–D) Zone of inhibition for (A) *S. epidermidis,* (B) *P. aeruginosa,* (C) *E. coli,* and (D) *S. aureus.* (E) Quantitative measurement of the zone of inhibition (mm). Data represent the mean \pm SD, and the * denotes significant difference compared to ciprofloxacin (P < 0.05) using one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

515 from hydrogel formulations was plotted as a function of time 516 and is presented in Figure 3C. The release profile is 517 characterized by a fast release in the first 10 h when 50% of the total silver amount is released, followed by a slow 518 519 continuous release for up to 24 h. This type of release profile 520 would be beneficial for treating wound infections since it 521 would allow for the rapid elimination of colonizing bacteria or 522 the disruption of established biofilms. It would also provide protection of the wound from further colonization and biofilm 523 establishment until the host immune system has recovered and 524 525 is capable of eradicating the bacterial pathogens. The slow and 526 sustained release of silver from the polymeric network is due to 527 the combination of the slow erosion of the hydrogel and the slow diffusion of silver nanoparticles providing a synergistic 528 ⁵²⁹ release profile favoring further therapeutic development.⁴

530 **Morphology of the Hydrogel.** The interior morphology 531 of the Pluronic hydrogel shows a relatively high porous structure in both the presence and absence of AgNPs (Figure 532 f4 4A–D). The images suggest that the overall microstructure of 533 f4 the hydrogel is not greatly influenced by the incorporation of 534 the AgNPs. As shown in Figure 4A-D, the interior 535 morphology of all hydrogels demonstrated a highly three- 536 dimensional porous structure with only slight variations in the 537 pore diameter, labeled with the yellow arrow. The pore size 538 was analyzed by measuring the longitudinal axis of each pore; 539 the representative pore size is labeled with the yellow arrow. 540 The results show that the mean pore size of the blank hydrogel 541 is 2.01 \pm 0.49 μ m compared to 1.40 \pm 0.4 μ m for the AgNP ₅₄₂ hydrogel (Figure 4A–D). The variation in pore size could be 543 explained by the higher cross-linking density of the AgNP- 544 loaded hydrogel compared to the blank control hydrogel, an 545 observation also reported for other similar systems.⁴⁴ The 546 small change in surface morphology could be attributed to the 547 interfacial interactions between silver nanoparticles and 548

f4



Figure 6. (A–C) Representative confocal microscopy images of Live/Dead assay of *P. aeruginosa, S. aureus,* and *S. epidermidis* bacteria and their corresponding quantitative analysis expressed as bacterial viability (%). Data are shown as mean \pm SD; the * denotes significant difference compared to the control, and # denotes significant difference compared to ciprofloxacin (*P* < 0.05) using one-way ANOVA followed by Dunnett's multiple comparison test. **P* < 0.05, **P* < 0.05, ***P* < 0.01, ****P* < 0.001, and *****P* < 0.0001.

549 Pluronic components. The silver nanoparticle distribution in a 550 hydrogel network was analyzed using energy-dispersive 551 spectroscopy (EDS). The corresponding EDS micrograph 552 confirms the presence of silver (Ag) and its homogenous 553 distribution in the hydrogel framework (Figure 4E–H).

Antibacterial Activity of the AgNP Hydrogel. The 554 555 antimicrobial performance of the AgNP hydrogel was studied 556 against four clinically relevant pathogens including S. 557 epidermidis, S. aureus, E. coli, and P. aeruginosa. These wound 558 pathogens are known to pose a major health threat in the 559 community due to the acquisition of multidrug resistance, 560 making treatment and their eradication very challenging. The 561 bactericidal capacities of the AgNP-loaded formulation (Gel 562 Ag) and the AgNPs alone (Sol Ag) were first assessed using a standard well diffusion assay against S. epidermidis, S. aureus, E. 563 564 coli, and P. aeruginosa (Figure 5A-E). Ciprofloxacin was used 565 as a positive control. The results show a clear inhibition of 566 bacterial growth by the AgNP gel and the AgNP solution, while the negative control (blank gel) did not produce a zone 567 of inhibition (ZOI) (Figure 5A-E). The measured zone of 568 569 inhibition is reported in Figure 5E. The formulation containing 570 AgNPs had a very similar ZOI compared to the AgNP 571 solution, demonstrating that the gel did not affect the 572 antibacterial potency of the nanoparticles. A similar zone of 573 inhibition was also observed when tested at lower concen-574 trations (25 μ g/g) of AgNPs (Figure S5).

f5

575 The bacterial viability in response to treatment was assessed 576 both qualitatively and quantitatively using the Live/Dead BacLight Bacterial viability kit. Bacterial cells were treated with 577 AgNP formulation for 24 h and then stained with fluorescent 578 dyes to determine the number of live (green) and dead (red) 579 cells. Representative images are shown in Figure 6. Bacteria 580 f6 exposed to blank gels or untreated controls stain predom- 581 inantly green, indicating the majority of viable cells. However, 582 when treated with AgNP-loaded hydrogels, viability of bacterial 583 cells significantly reduced to >97, 95, and >96% for P. 584 aeruginosa, S. aureus, and S. epidermidis, respectively (Figure 585 6A-C). In contrast, the equal concentration of ciprofloxacin 586 resulted in 84, 81, and 85% viability reduction for P. aeruginosa, 587 S. aureus, and S. epidermidis, respectively. These results indicate 588 that AgNPs could increase the membrane permeability of 589 bacteria significantly, which is one of the indications of a 590 bactericidal effect. AgNPs are known to kill bacteria by a 591 multifaceted mechanism including binding to DNA and 592 proteins and damaging the cell membrane.⁴⁵ We speculate 593 that the latter plays a major role in defining the antibacterial 594 activity of the present composition. This opinion is based on 595 the ultrasmall size of the AgNPs and the ease of overcoming 596 barriers to penetrate the bacterial cell membrane.

In Vitro Antibiofilm Assay. The effective disruption and 598 removal of bacterial biofilms is a significant clinical challenge as 599 surgical debridement is not always effective and biofilms can 600 reform quickly. Biofilms are a complex community in which 601 the bacterial phenotype differs from that of planktonic 602 counterparts.⁴⁶ The formation of a biofilm greatly reduces 603 the effectiveness of antibiotics, diminishes the capacity of the 604



Figure 7. (A) Schematic illustration of biofilm formation and staining using crystal violet. (B–D) Eradication of single-species biofilm of *S. epidermidis*, *P. aeruginosa*, and *S. aureus* and representative images of well plates showing the intensity of crystal violet staining. (E) Schematic illustration of the colony wound biofilm model. (F) Log₁₀ reduction of the bacterial biofilm colony compared to the control following treatment with AgNPs and ciprofloxacin. Data are shown as mean \pm SD; the * denotes significant difference compared to the control, and # denotes significant difference compared to ciprofloxacin (*P* < 0.05) using one-way ANOVA followed by Dunnett's multiple comparison test. **P* < 0.05, **P* < 0.05, ***P* < 0.01, ****P* < 0.001, and *****P* < 0.0001.

605 immune system to fight the bacteria, and contributes to the 606 development of antimicrobial resistance. We assessed the 607 effectiveness of the AgNP-loaded hydrogel to disrupt and 608 eliminate existing biofilms composed of both single and 609 multiple clinically relevant species. For this study, bacterial 610 biofilms were first established on a 96-well plate, treated with 611 the AgNP formulation, and stained with crystal violet (Figure ₆₁₂ 7A). The results for a single-species biofilms of S. epidermidis, 613 S. aureus, and P. aeruginosa are shown in Figure 7A-C. We 614 found that biofilm disruption and elimination were a $_{615}$ concentration-dependent phenomenon with 50 μ g/g AgNP-616 loaded gel resulting in significant biofilm disruption for S. 617 epidermidis, P. aeruginosa, and S. aureus. This is evident in 618 Figure 7 and in the supporting image showing a reduction in 619 biofilm biomass in the treated sample compared to the 620 nontreated group. Interestingly, 50 μ g/g AgNP gel showed a 621 significantly greater antibiofilm effect than ciprofloxacin at the 622 same concentration against *P. aeruginosa*. This finding indicates

f7

f7

that bacterial biofilms are greatly susceptible to AgNP-loaded 623 gels. 624

In Vitro Wound Biofilm Model. Evaluating antibiofilm 625 activities using in vivo models is challenging; hence, in vitro 626 models that closely resemble a wound bed are often utilized. In 627 this study, biofilms were grown on a nanoporous polycar- 628 bonate membrane, supplemented with artificial acute wound 629 fluid (human serum containing 5% blood and 1% peptone). 630 Additionally, the agar was supplemented with chopped meat- 631 based nutrients (brain heart infusion, BHI), as well as 5% 632 blood plasma, to replicate conditions providing ample nutrient 633 supply to pathogens similar to conditions encountered in the 634 clinical wound environment. A schematic representation of the 635 wound biofilm model is shown in Figure 7E. The data are 636 presented as a log reduction of the untreated control compared 637 to treated groups (Figure 7F). The treatment groups had a 638 significant reduction in the number of viable bacteria after 24 639 h, regardless of the bacterial strains (Figure 7F). The result 640 showed that 25 and 50 μ g/g gel had an average viable 641

I

www.acsami.org



Figure 8. Three-dimensional CLSM images of the *P. aeruginosa* biofilm before (A) and after treatment with the blank gel (B) and the gel loaded with AgNPs (C, D). SYTO9 stains bacteria live (green), while propidium iodide stains bacteria dead (red).

642 reduction of between 4 and 5.5 \log_{10} reductions compared to 643 the untreated control across the bacterial strains. This was also 644 comparable to ciprofloxacin at 50 μ g/mL showing an average 645 reduction of 4.5 \log_{10} except for *P. aeruginosa*, which showed 646 significantly higher susceptibility (Figure 7F). However, the 647 blank gel was only able to reduce approx. 1.5 \log_{10} bacterial 648 reduction. These results further support the potent antibiofilm 649 activity of AgNPs against these bacterial strains, consistent with 650 our other *in vitro* biofilm studies. This study demonstrates the 651 potential of the AgNP gel to eradicate established biofilms in a 652 much more complex woundlike environment not just in 653 standard culture plates.

Biofilm Eradication Post AgNP Treatment. To obtain 654 655 further insights into the antibiofilm activity of the AgNP-656 loaded gel formulation, we employed confocal laser scanning 657 microscopy (CLSM) to study the biofilm structure and 658 eradication. In this study, P. aeruginosa was used because it 659 is recognized as one of the most common bacterial species 660 associated with persistent chronic wound infection as well as 661 its ability to form strong adherent biofilms.⁴⁷ The confocal 662 micrographs were taken across the depth of the biofilm to 663 illustrate both structure thickness and bacterial cell viability. As 664 shown in Figure 8A,B, control samples were composed of an 665 intact thick multilayered biofilm that covered the entire 666 surface. The Live/Dead staining showed mostly healthy cells 667 (green staining). The result was similar when the biofilm was 668 treated with gel, which did not contain AgNPs. In contrast, 669 images of biofilms treated with gels containing 25 and 50 μ g/g 670 AgNPs depicted dispersed structures and extensive cell death 671 (Figure 8C,D). In fact, when the concentration of AgNPs was $_{672}$ increased to 50 μ g/g, the majority of the biofilm biomass was 673 detached from the surface, and the remaining colonies were 674 killed. This observation was consistent with the crystal violet $_{675}$ assay, demonstrating that 50 μ g/g formulation was an effective 676 concentration to eradicate established biofilms.

SEM Analysis of Bacteria Morphology. SEM imaging 677 was used to determine morphological changes on the surface of 678 *P. aeruginosa* cells and biofilm structure treated with the AgNP- 679 containing gel. Visualization of bacterial biofilms with SEM 680 showed a wide spectrum of morphological differences in the 681 biofilm structure, as indicated with the yellow arrows (Figure 682 f9 9A–D). Notably, biofilms treated with the AgNP formulation 683 f9



Figure 9. (A-D) Representative scanning electron microscope images of the *P. aeruginosa* biofilm structure before (A) and after treatment with the blank gel (B) and the gel loaded with AgNP formulation extracts (C, D). Inset images show the bacterial morphology at higher magnification 50 000×.

showed few scattered cell aggregates compared to the $_{684}$ untreated biofilms, which were characterized by an intact $_{685}$ structure connected with the extracellular matrix. The high- $_{686}$ magnification micrographs clearly show that treated biofilms $_{687}$ had undergone severe structural damage as the cells were $_{688}$ ruptured, lysed, and showed clear signs of membrane blebbing. $_{689}$

www.acsami.org



Figure 10. Three-dimensional reconstruction of the multispecies bacterial biofilm and crystal violet staining. (A) Absorbance of the crystal violet staining of biofilm biomass, (B) CLSM images of biofilm either left untreated for 24 h (B) or treated with blank gel (C), 50 μ g/mL ciprofloxacin (D), and 25 and 50 μ g/g AgNP gel (E, F), respectively. Data are shown as mean ±SD; the * denotes significant difference compared to the control and # denotes significant difference compared to ciprofloxacin (*P* < 0.05) using one-way ANOVA followed by Dunnett's multiple comparison test. **P* < 0.05, **P* < 0.05, **P* < 0.01, ****P* < 0.001, and *****P* < 0.0001.

690 These pronounced changes could be attributed to the close 691 interaction of the AgNPs and Ag ions with the bacterial 692 membrane as well as the possible formation of reactive oxygen 693 species.^{48,49} Indeed, the application of AgNPs (50 $\mu g/g$) 694 increased the level of intracellular reactive oxygen species by 695 35% in comparison to the untreated control, while the blank 696 gel resulted only in a minimal 10% increase (Figure S6). This 697 is consistent with previous studies showing the concentration-698 dependent oxidative stress following exposure of AgNPs 699 against bacteria.^{50,51} The slight increase of ROS in response 700 to the blank is expected due to the reactivity and sensitivity of the DCHF-DA; however, this minimal increase is physiolog-701 702 ically not relevant and unable to cause damage to the cells. 703 However, the 35% increase in oxidative stress observed 704 following AgNP treatment disrupts the cell membrane 705 integrity, leading to leakage of cytoplasmic contents and 706 ultimately bacterial cell death.⁵² The excellent bactericidal activity of the gel formulation can be attributed to the small 707 size of the AgNPs, which provides greater surface area and 708 709 more contact sites for stronger and more frequent bacterial 710 interaction. This proposed mechanism is consistent with published studies.⁵³ Importantly, the small AgNP size suggests 711 712 possible efficient penetration to the biofilm matrix to mediate a greater degree of eradication. 713

Untreated biofilms were observed to be much denser and 714 715 richer in the extracellular matrix. The significantly higher cell 716 density with unaltered membrane morphology suggests a 717 normal healthy structure, as is clearly visible at highermagnification images (Figure 9A,B), compared to treated 718 groups (Figure 9C,D). The SEM analysis of the biofilm 719 corroborates well with the results of crystal violet staining and 720 confocal image analysis presented above. The AgNP-loaded gel 721 formulation developed in this study has a very potent 722 antimicrobial activity and a biofilm elimination capacity that 723 is attributed to the ultrasmall AgNP size. The gel activity is 724 725 superior to many published studies and commercial anti-726 microbial products.^{48,54} Compared to a previous study,⁵⁵ 727 which required a significantly higher concentration of 125 μ g/ 728 mL AgNPs to eliminate P. aeruginosa biofilms, results of the present study show significant benefits in the eradication of *P*. 729 *aeruginosa* biofilms at significantly lower AgNP doses, which is 730 clinically significant as it reduces toxicity to mammalian cells 731 and tissue. Thus, the slower ion leaching from the hydrogel 732 facilitates improved delivery of silver ions for enhanced activity. 733

Multispecies Bacterial Biofilm. The effectiveness of the 734 developed AgNP gel against multispecies biofilms was also 735 investigated. This is important and clinically relevant as most 736 wound infections are composed of multiple different bacteria 737 living in close proximity or as a biofilm. For this experiment, S. 738 epidermidis, P. aeruginosa, and S. aureus were combined in equal 739 concentrations and grown on 96-well plates for 24 h to 740 facilitate biofilm establishment. The combination of bacteria 741 was chosen based on their presence in typical chronic wounds 742 and their notorious biofilm-forming capability either individ- 743 ually or in combinations.⁵⁶ The result indicated that the mixed 744 bacteria formed a significantly larger biomass as determined by 745 crystal violet staining (Figure 10A). This observation indicates 746 f10 that the bacteria may benefit from engagement in a mutually 747 cooperative interaction to promote growth and pathogenicity, 748 as previously reported.⁵⁷ 749

Hydrogels that contained 50 μ g/g AgNPs were able to 750 eradicate a significant amount of the established multispecies 751 biofilm, indicating improved activity compared to an equal 752 concentration of ciprofloxacin (Figure 10A). Additionally, the 753 antibiofilm activities of the AgNP formulation were further 754 examined visually using CLSM observation of biofilm layers 755 stained with the Live/Dead viability kit. As shown in Figure 756 10B-F, untreated controls were characterized by intact 757 biofilms with predominant viable bacteria (green staining). 758 In contrast, biofilms treated with either ciprofloxacin or AgNP 759 gel showed notable cell death (red staining) and biofilm 760 detachment, indicated by the reduced biofilm thickness. As 761 expected, the number of dead cells increased when treated with 762 AgNPs at the highest dose. We hypothesize that the 763 remarkable capacity of the gel formulation to eliminate 764 established biofilms is due to the ultrasmall size of the 765 AgNPs, which enhances the capacity of AgNPs to disperse the 766 biofilm and kill the bacteria. Hence, this study reports a 767



Figure 11. Representative fluorescence microscope images of human foreskin fibroblast (HFF) (A) and HaCaT (B) morphology in the presence or absence of AgNP formulation and their corresponding cell viability after 24 h of exposure. Data are represented as mean \pm SD; the * denotes significant difference compared to the control (P < 0.05) using one-way ANOVA followed by Dunnett's multiple comparison test, and ns denotes no significance. ns, P > 0.05, *P < 0.05, *P < 0.01, ***P < 0.001, and ****P < 0.0001.

768 substantial eradication capacity of this novel formulation 769 against established multispecies biofilms and opens a 770 promising and exciting new avenue in controlling bacterial 771 biofilms, which could improve clinical practice and treatment 772 and management of patients suffering from infected chronic 773 wounds.

Evaluation of Cellular Morphology and Cytotoxicity. 774 In addition to the excellent antibacterial capacity, it is 775 776 important to evaluate the possible toxicity of the developed 777 hydrogel on human cells. We selected primary human foreskin fibroblasts (HFFs) and human keratinocytes (HaCaTs) as 778 these are the main cell types found in the wound-healing 779 780 process. As shown in Figure 11A,B, the most effective antibacterial hydrogel containing 50 μ g/g AgNPs showed no 781 obvious cytotoxicity to both cell types within 24 h, very similar 782 to the untreated control. The viability of both cells types was 783 found to be above 80%, which is considered as nontoxic 784 785 according to the International Standard ISO 2009 "Biological 786 evaluation of medical devices".58 The increased viability 787 observed here could be explained by the higher tolerance of mammalian cells to silver compared to bacteria indicated in 788 other published studies.⁵⁹ 789

The cytocompatibility of the AgNP hydrogel formulation 790 was further confirmed by studying its effects on the cell 791 morphology by assessing the cytoskeletal actin structure to 792 determine whether AgNPs induce changes in the morphology 793 and adhesion of the cells. Fluorescent images of both HaCaTs 794 and HFFs demonstrated no significant changes in the cell 795 morphology and the associated actin cytoskeletal structure 796 (Figure 11A,B). Notably, treated cells appeared healthy and 797 comparable to the untreated controls. This suggests a high 798 level of biocompatibility of the AgNP Pluronic hydrogel with 799 human skin cells even after exposure greater than 24 h. Taken 800 together, the antibacterial hydrogel developed in this study 801 revealed a considerable antimicrobial activity against a broad 802 spectrum of bacteria, including established multispecies 803 biofilms, accompanied by minimal cytotoxicity to mammalian 804 cells in vitro. These results offer great promise for future 805 applications of the developed hydrogel using in vivo studies to 806 investigate clinically relevant infected wounds. Hence, forth- 807 coming work will focus on preclinical studies in small- and 808

809 large-animal models of wound infection and in-depth 810 mechanistic interrogation of the antibacterial potency of the 811 composition.

812 CONCLUSIONS

813 We have developed a novel thermosensitive hydrogel 814 composition loaded with ultrasmall AgNPs, which provide a 815 continuous release of silver ions for periods longer than 24 h. 816 The gel has very high efficacy against clinically significant 817 Gram-negative and Gram-positive bacteria. Importantly, we 818 found that the gel has the capacity to disrupt and eradicate 819 established biofilms composed of not only single bacterial 820 species but also multispecies pathogens. Biocompatibility 821 studies using human foreskin fibroblasts and human 822 keratinocytes showed no apparent (or clinically relevant 823 <20%) toxicity to skin cells, which play a critical role in 824 wound healing and tissue regeneration. The potent anti-825 bacterial activity of the gel developed in this study could be 826 largely attributed to well-dispersed ultrasmall AgNPs in a 827 complex hydrogel framework that facilitates the continuous 828 and sustained release of silver ions from the hydrogel, hence 829 providing an enhanced capacity to interact with the bacterial 830 membranes and causing significant bacterial cell damage and 831 death. The results presented here open exciting avenues for 832 creating advanced wound management products with superior 833 antibacterial performance, which then could become an 834 effective therapeutic option for difficult-to-treat infected 835 wounds.

836 ASSOCIATED CONTENT

837 Supporting Information

838 The Supporting Information is available free of charge at 839 https://pubs.acs.org/doi/10.1021/acsami.0c09414.

840	Pluronic F-127 hydrogel formulation composition; DLS
841	and UV-vis spectroscopy of AgNP formulation on days

842 0, 7, 30, and 60; representative images of a zone of

- inhibition of AgNPs (25 μ g/g); intracellular reactive
- 844 oxygen species generation in *P. aeruginosa* after exposure
- to AgNP formulation and H_2O_2 (PDF)

846 **AUTHOR INFORMATION**

847 Corresponding Authors

- 848 Nirmal Goswami Academic Unit of STEM, University of
- 849 South Australia, Mawson Lakes, SA 5095, Australia; Materials
- 850 Chemistry Department, CSIR-Institute of Minerals and
- 851 Materials Technology, Bhubaneswar 751013, India;
- 852 © orcid.org/0000-0002-8950-6459; Phone: +91-9330-897
- 853 344; Email: ngoswami@immt.res.in
- Krasimir Vasilev Future Industries Institute and Academic
 Unit of STEM, University of South Australia, Mawson Lakes,
- Unit of STEM, University of South Australia, Mawson La
 SA 5095, Australia;

 orcid.org/0000-0003-3534-4754;
- 857 Phone: +61 8 830 25697; Email: Krasimir.vasilev@
- 858 unisa.edu.au

859 Authors

- Hanif Haidari UniSA Clinical & Health Sciences and Future
 Industries Institute, University of South Australia, Adelaide, SA
 5000, Australia
- 863 Zlatko Kopecki UniSA Clinical & Health Sciences and Future
 864 Industries Institute, University of South Australia, Adelaide, SA
 865 S000 Australia
- 865 5000, Australia

Richard Bright – Academic Unit of STEM, University of South	866
Australia, Mawson Lakes, SA 5095, Australia	867
Allison J. Cowin – UniSA Clinical & Health Sciences and	868
Future Industries Institute, University of South Australia,	869
Adelaide, SA 5000, Australia; orcid.org/0000-0003-2885-	870
2080	871
Sanjay Garg – UniSA Clinical & Health Sciences, University of	872
South Australia, Adelaide, SA 5000, Australia	873
Complete contact information is available at:	874
https://pubs.acs.org/10.1021/acsami.0c09414	875

Author Contributions

Notes

The manuscript was written through the contributions of all 877 authors. All authors have approved the final version of the 878 manuscript. 879

The authors declare no competing financial interest. 881

ACKNOWLEDGMENTS

K.V. thanks ARC for DP15104212, NHMRC for fellowship 883 APP1122825, and Project grant APP1032738 and the 884 Alexander von Humboldt Foundation for Fellowship for 885 Experienced Researchers. A.J.C. is supported by the 886 NHMRC Senior Research Fellowship (GNT #1102617). 887 Z.K. is supported by the University of South Australia Future 888 Industries Institute Foundation Fellowship and DEBRA 889 Australia Research Grant. 890

ABBREVIATIONS

MSA, mercaptosuccinic acid	892
AgNPs, silver nanoparticles	893
CFU, colony-forming units	894
CLSM, confocal laser scanning microscopy	895
CV, crystal violet	896
DAPI, diamido-2 phenyllindole dihydrochloride	897
DCFH-DA, 2',7'-dichlorofluorescin diacetate	898
DLS, dynamic light scattering	899
DMEM, Dulbecco's modified Eagle's medium	900
EDS, energy-dispersive X-ray spectrometry	901
HaCaTs, human keratinocytes	902
HFFs, human foreskin fibroblasts	903
HMDS, hexamethyldisilazane	904
PF-127, pluronic F-127	905
PG, propylene glycol	906
P. aeruginosa, Pseudomonas aeruginosa	907
ROS, reactive oxygen species	908

REFERENCES

(1) Podolsky, S. H. The evolving response to antibiotic resistance 910 (1945–2018). *Palgrave Commun.* **2018**, *4*, 1–8. 911

(2) Barriere, S. L. Clinical, economic and societal impact of 912 antibiotic resistance. *Expert Opin. Pharmacother.* 2015, 16, 151–153. 913
(3) O'Neill, J. Antimicrobial Resistance: Tackling a Crisis for the 914 Health and Wealth of Nations (London). Review on Antimicrobial 915 Resistance, 2014. 916

(4) Chowdhury, N. R.; MacGregor-Ramiasa, M.; Zilm, P.; Majewski, 917 P.; Vasilev, K. 'Chocolate' silver nanoparticles: Synthesis, antibacterial 918 activity and cytotoxicity. *J. Colloid Interface Sci.* **2016**, 482, 151–158. 919 (5) Wu, J.; Li, F.; Hu, X.; Lu, J.; Sun, X.; Gao, J.; Ling, D. Responsive 920 Assembly of Silver Nanoclusters with a Biofilm Locally Amplified 921 Bactericidal Effect to Enhance Treatments against Multi-Drug-922 Resistant Bacterial Infections. *ACS Cent. Sci.* **2019**, *5*, 1366–1376. 923

876

880

882

891

909

924 (6) Chen, H.; Wubbolts, R. W.; Haagsman, H. P.; Veldhuizen, E. J. 925 A. Inhibition and Eradication of *Pseudomonas aeruginosa* Biofilms by 926 Host Defence Peptides. *Sci. Rep.* **2018**, *8*, No. 10446.

927 (7) Wu, H.; Moser, C.; Wang, H.-Z.; Høiby, N.; Song, Z.-J. 928 Strategies for combating bacterial biofilm infections. *Int. J. Oral Sci.* 929 **2015**, *7*, 1–7.

930 (8) García-Astrain, C.; Chen, C.; Burón, M.; Palomares, T.; Eceiza,
931 A.; Fruk, L.; Corcuera, M. Á.; Gabilondo, N. Biocompatible Hydrogel
932 Nanocomposite with Covalently Embedded Silver Nanoparticles.
933 Biomacromolecules 2015, 16, 1301–1310.

934 (9) Taheri, S.; Cavallaro, A.; Christo, S. N.; Smith, L. E.; Majewski, 935 P.; Barton, M.; Hayball, J. D.; Vasilev, K. Substrate independent silver 936 nanoparticle based antibacterial coatings. *Biomaterials* **2014**, *35*, 937 4601–4609.

938 (10) Koo, H.; Allan, R. N.; Howlin, R. P.; Stoodley, P.; Hall-939 Stoodley, L. Targeting microbial biofilms: current and prospective 940 therapeutic strategies. *Nat. Rev. Microbiol.* **2017**, *15*, 740–755.

941 (11) Flemming, H.-C.; Wingender, J.; Szewzyk, U.; Steinberg, P.;
942 Rice, S. A.; Kjelleberg, S. Biofilms: an emergent form of bacterial life.
943 Nat. Rev. Microbiol. 2016, 14, 563–575.

944 (12) Yang, L.; Liu, Y.; Wu, H.; Høiby, N.; Molin, S.; Song, Z. J. 945 Current understanding of multi-species biofilms. *Int. J. Oral Sci.* 2011, 946 3, 74–81.

947 (13) Burmølle, M.; Webb, J. S.; Rao, D.; Hansen, L. H.; Sørensen, S.
948 J.; Kjelleberg, S. Enhanced Biofilm Formation and Increased
949 Resistance to Antimicrobial Agents and Bacterial Invasion Are Caused
950 by Synergistic Interactions in Multispecies Biofilms. *Appl. Environ.*951 *Microbiol.* 2006, 72, 3916–3923.

(14) Liu, W.; Jacquiod, S.; Brejnrod, A.; Russel, J.; Burmølle, M.;
Sørensen, S. J. Deciphering links between bacterial interactions and
spatial organization in multispecies biofilms. *ISME J.* 2019, *13*, 3054–
3066.

956 (15) Stewart, E. J.; Payne, D. E.; Ma, T. M.; VanEpps, J. S.; Boles, B. 957 R.; Younger, J. G.; Solomon, M. J. Effect of Antimicrobial and 958 Physical Treatments on Growth of Multispecies Staphylococcal 959 Biofilms. *Appl. Environ. Microbiol.* **2017**, *83*, e03483–e03499.

960 (16) Yuan, X.; Setyawati, M. I.; Leong, D. T.; Xie, J. Ultrasmall Ag 961 +-rich nanoclusters as highly efficient nanoreservoirs for bacterial 962 killing. *Nano Res.* **2014**, *7*, 301–307.

963 (17) Goreham, R. V.; Mierczynska, A.; Pierce, M.; Short, R. D.;
964 Taheri, S.; Bachhuka, A.; Cavallaro, A.; Smith, L. E.; Vasilev, K. A
965 substrate independent approach for generation of surface gradients.
966 Thin Solid Films 2013, 528, 106–110.

967 (18) Tian, Y.; Qi, J.; Zhang, W.; Cai, Q.; Jiang, X. Facile, One-Pot 968 Synthesis, and Antibacterial Activity of Mesoporous Silica Nano-969 particles Decorated with Well-Dispersed Silver Nanoparticles. *ACS* 970 *Appl. Mater. Interfaces* **2014**, *6*, 12038–12045.

971 (19) Rai, M.; Yadav, A.; Gade, A. Silver nanoparticles as a new 972 generation of antimicrobials. *Biotechnol. Adv.* **2009**, *27*, 76–83.

973 (20) Haidari, H.; Goswami, N.; Bright, R.; Kopecki, Z.; Cowin, A. J.; 974 Garg, S.; Vasilev, K. The interplay between size and valence state on 975 the antibacterial activity of sub-10 nm silver nanoparticles. *Nanoscale* 976 *Adv.* **2019**, *1*, 2365–2371.

977 (21) Zheng, K.; Setyawati, M. I.; Leong, D. T.; Xie, J. Antimicrobial 978 silver nanomaterials. *Coord. Chem. Rev.* **2018**, 357, 1–17.

979 (22) Liu, Y.; Lu, W.-L.; Wang, J.-C.; Zhang, X.; Zhang, H.; Wang, X.-980 Q.; Zhou, T.-Y.; Zhang, Q. Controlled delivery of recombinant 981 hirudin based on thermo-sensitive Pluronic F127 hydrogel for 982 subcutaneous administration: In vitro and in vivo characterization. *J.* 983 *Controlled Release* **2007**, *117*, 387–395.

984 (23) Shachaf, Y.; Gonen-Wadmany, M.; Seliktar, D. The 985 biocompatibility of PluronicF127 fibrinogen-based hydrogels. *Bio*-986 materials **2010**, *31*, 2836–2847.

987 (24) Elluru, M.; Ma, H.; Hadjiargyrou, M.; Hsiao, B. S.; Chu, B. 988 Synthesis and characterization of biocompatible hydrogel using 989 Pluronics-based block copolymers. *Polymer* **2013**, *54*, 2088–2095.

990 (25) Ruel-Gariépy, E.; Leroux, J.-C. In situ-forming hydrogels—
991 review of temperature-sensitive systems. *Eur. J. Pharm. Biopharm.*992 2004, 58, 409-426.

(26) Bhattarai, N.; Ramay, H. R.; Gunn, J.; Matsen, F. A.; Zhang, M. 993 PEG-grafted chitosan as an injectable thermosensitive hydrogel for 994 sustained protein release. *J. Controlled Release* **2005**, *103*, 609–624. 995 (27) Haidari, H.; Zhang, Q.; Melville, E.; Kopecki, Z.; Song, Y.; 996 Cowin, A. J.; Garg, S. Development of Topical Delivery Systems for 997 Flightless Neutralizing Antibody. *J. Pharm. Sci.* **2017**, *106*, 1795– 998 1804. 999

(28) Thet, N. T.; Alves, D. R.; Bean, J. E.; Booth, S.; Nzakizwanayo, 1000 J.; Young, A. E. R.; Jones, B. V.; Jenkins, A. T. A. Prototype 1001 Development of the Intelligent Hydrogel Wound Dressing and Its 1002 Efficacy in the Detection of Model Pathogenic Wound Biofilms. *ACS* 1003 *Appl. Mater. Interfaces* **2016**, *8*, 14909–14919. 1004

(29) Bhargava, A.; Pareek, V.; Roy Choudhury, S.; Panwar, J.; 1005 Karmakar, S. Superior Bactericidal Efficacy of Fucose-Functionalized 1006 Silver Nanoparticles against *Pseudomonas aeruginosa* PAO1 and 1007 Prevention of Its Colonization on Urinary Catheters. *ACS Appl.* 1008 *Mater. Interfaces* **2018**, *10*, 29325–29337. 1009

(30) Su, H.-L.; Chou, C.-C.; Hung, D.-J.; Lin, S.-H.; Pao, I. C.; Lin, 1010 J.-H.; Huang, F.-L.; Dong, R.-X.; Lin, J.-J. The disruption of bacterial 1011 membrane integrity through ROS generation induced by nanohybrids 1012 of silver and clay. *Biomaterials* **2009**, *30*, 5979–5987. 1013

(31) Regiel-Futyra, A.; Kus-Liśkiewicz, M.; Sebastian, V.; Irusta, S.; 1014 Arruebo, M.; Kyzioł, A.; Stochel, G. Development of noncytotoxic 1015 silver–chitosan nanocomposites for efficient control of biofilm 1016 forming microbes. *RSC Adv.* **2017**, *7*, 52398–52413. 1017

(32) Kopecki, Z.; O'Neill, G. M.; Arkell, R. M.; Cowin, A. J. 1018 Regulation of Focal Adhesions by Flightless I Involves Inhibition of 1019 Paxillin Phosphorylation via a Rac1-Dependent Pathway. *J. Invest.* 1020 Dermatol. **2011**, 131, 1450–1459. 1021

(33) Yuan, X.; Setyawati, M. I.; Tan, A. S.; Ong, C. N.; Leong, D. T.; 1022 Xie, J. Highly luminescent silver nanoclusters with tunable emissions: 1023 cyclic reduction-decomposition synthesis and antimicrobial proper- 1024 ties. NPG Asia Mater. **2013**, *5*, No. e39. 1025

(34) Li, J.; Mooney, D. J. Designing hydrogels for controlled drug 1026 delivery. *Nat. Rev. Mater.* **2016**, *1*, No. 16071. 1027

(35) Hokett, S. D.; Cuenin, M. F.; O'Neal, R. B.; Brennan, W. A.; 1028 Strong, S. L.; Runner, R. R.; McPherson, J. C.; Van Dyke, T. E. 1029 Pluronic Polyol Effects on Human Gingival Fibroblast Attachment 1030 and Growth. J. Periodontol. **2000**, *71*, 803–809. 1031

(36) Sood, N.; Bhardwaj, A.; Mehta, S.; Mehta, A. Stimuli- 1032 responsive hydrogels in drug delivery and tissue engineering. *Drug* 1033 *Delivery* **2016**, 23, 748–770. 1034

(37) Ivanova, R.; Lindman, B.; Alexandridis, P. Evolution in 1035 Structural Polymorphism of Pluronic F127 Poly(ethylene oxide) – 1036 Poly(propylene oxide) Block Copolymer in Ternary Systems with 1037 Water and Pharmaceutically Acceptable Organic Solvents: From 1038 "Glycols" to "Oils". *Langmuir* **2000**, *16*, 9058–9069. 1039

(38) Islam, M. T.; Rodríguez-Hornedo, N.; Ciotti, S.; Ackermann, C. 1040 Rheological Characterization of Topical Carbomer Gels Neutralized 1041 to Different pH. *Pharm. Res.* **2004**, *21*, 1192–1199. 1042

(39) Uman, S.; Dhand, A.; Burdick, J. A. Recent advances in shear- 1043 thinning and self-healing hydrogels for biomedical applications. *J.* 1044 *Appl. Polym. Sci.* **2020**, *137*, No. 48668. 1045

(40) Tang, Y.-F.; Du, Y.-M.; Hu, X.-W.; Shi, X.-W.; Kennedy, J. F. 1046 Rheological characterisation of a novel thermosensitive chitosan/ 1047 poly(vinyl alcohol) blend hydrogel. *Carbohydr. Polym.* **2007**, *67*, 491– 1048 499. 1049

(41) Afinjuomo, F.; Fouladian, P.; Parikh, A.; Barclay, T. G.; Song, 1050 Y.; Garg, S. Preparation and Characterization of Oxidized Inulin 1051 Hydrogel for Controlled Drug Delivery. *Pharmaceutics* **2019**, *11*, 1052 356–377. 1053

(42) Dai, X.; Zhang, Y.; Gao, L.; Bai, T.; Wang, W.; Cui, Y.; Liu, W. 1054 A Mechanically Strong, Highly Stable, Thermoplastic, and Self- 1055 Healable Supramolecular Polymer Hydrogel. *Adv. Mater.* **2015**, *27*, 1056 3566–3571. 1057

(43) Rolim, W. R.; Pelegrino, M. T.; de Araújo Lima, B.; Ferraz, L. 1058 S.; Costa, F. N.; Bernardes, J. S.; Rodigues, T.; Brocchi, M.; Seabra, A. 1059 B. Green tea extract mediated biogenic synthesis of silver nano- 1060 1061 particles: Characterization, cytotoxicity evaluation and antibacterial 1062 activity. *Appl. Surf. Sci.* **2019**, *463*, 66–74.

1063 (44) Liu, X.; Gan, H.; Hu, C.; Sun, W.; Zhu, X.; Meng, Z.; Gu, R.; 1064 Wu, Z.; Dou, G. Silver sulfadiazine nanosuspension-loaded 1065 thermosensitive hydrogel as a topical antibacterial agent. *Int. J.* 1066 Nanomed. **2019**, *14*, 289–300.

1067 (45) Le Ouay, B.; Stellacci, F. Antibacterial activity of silver 1068 nanoparticles: A surface science insight. *Nano Today* **2015**, *10*, 339– 1069 354.

1070 (46) Richter, K.; Facal, P.; Thomas, N.; Vandecandelaere, I.; 1071 Ramezanpour, M.; Cooksley, C.; Prestidge, C. A.; Coenye, T.; 1072 Wormald, P.-J.; Vreugde, S. Taking the Silver Bullet Colloidal Silver 1073 Particles for the Topical Treatment of Biofilm-Related Infections. 1074 ACS Appl. Mater. Interfaces **2017**, *9*, 21631–21638.

1075 (47) Bjarnsholt, T. The role of bacterial biofilms in chronic 1076 infections. *APMIS, Suppl.* **2013**, *121*, 1–58.

1077 (48) Liu, J.; Li, S.; Fang, Y.; Zhu, Z. Boosting antibacterial activity 1078 with mesoporous silica nanoparticles supported silver nanoclusters. *J.* 1079 *Colloid Interface Sci.* **2019**, *555*, 470–479.

1080 (49) McShan, D.; Ray, P. C.; Yu, H. Molecular Toxicity Mechanism 1081 of Nanosilver. J. Food Drug Anal. 2014, 22, 116–127.

1082 (50) Choi, O.; Hu, Z. Size Dependent and Reactive Oxygen Species 1083 Related Nanosilver Toxicity to Nitrifying Bacteria. *Environ. Sci.* 1084 *Technol.* **2008**, 42, 4583–4588.

1085 (51) Jin, J.-C.; Wu, X.-J.; Xu, J.; Wang, B.-B.; Jiang, F.-L.; Liu, Y. 1086 Ultrasmall silver nanoclusters: Highly efficient antibacterial activity 1087 and their mechanisms. *Biomater. Sci.* **2017**, *5*, 247–257.

1088 (52) Zhang, L.; Wu, L.; Si, Y.; Shu, K. Size-dependent cytotoxicity of 1089 silver nanoparticles to Azotobacter vinelandii: Growth inhibition, cell 1090 injury, oxidative stress and internalization. *PLoS One* **2018**, *13*, 1091 No. e0209020.

1092 (53) Morones, J. R.; Jose Luis, E.; Alejandra, C.; Katherine, H.; Juan, 1093 B. K.; Jose Tapia, R.; Miguel Jose, Y. The bactericidal effect of silver 1094 nanoparticles. *Nanotechnology* **2005**, *16*, 2346–2353.

1095 (54) Burd, A.; Kwok, C. H.; Hung, S. C.; Gu, H.; Hua, G.; Lam, W. 1096 K.; Huang, L. A comparative study of the cytotoxicity of silver-based 1097 dressings in monolayer cell, tissue explant, and animal models. *Wound* 1098 *Repair Regen.* **2007**, *15*, 94–104.

1099 (55) Alvarado-Gomez, E.; Martínez-Castañon, G.; Sanchez-Sanchez, 1100 R.; Ganem-Rondero, A.; Yacaman, M. J.; Martinez-Gutierrez, F. 1101 Evaluation of anti-biofilm and cytotoxic effect of a gel formulation 1102 with Pluronic F-127 and silver nanoparticles as a potential treatment 1103 for skin wounds. *Mater. Sci. Eng., C* **2018**, *92*, 621–630.

1104 (56) Dosler, S.; Karaaslan, E. Inhibition and destruction of 1105 *Pseudomonas aeruginosa* biofilms by antibiotics and antimicrobial 1106 peptides. *Peptides* **2014**, *62*, 32–37.

1107 (57) Fang, K.; Jin, X.; Hong, S. H. Probiotic *Escherichia coli* inhibits 1108 biofilm formation of pathogenic *E. coli* via extracellular activity of 1109 DegP. *Sci. Rep.* **2018**, *8*, No. 592.

1110 (58) ISO, I.S.. Biological Evaluation of Medical Devices. *Part 5: Tests* 1111 for In Vitro Cytotoxicity; ISO: Switzerland, 2009.

(59) Vasilev, K.; Sah, V.; Anselme, K.; Ndi, C.; Mateescu, M.;
Dollmann, B.; Martinek, P.; Ys, H.; Ploux, L.; Griesser, H. J. Tunable
antibacterial coatings that support mammalian cell growth. *Nano Lett.*2010, *10*, 202–207.